eShowcase: Clin'Form
Digital writing solution speeds up data harvest while ensuring traceability and capture ease
Digital writing solution speeds up data harvest while ensuring traceability and capture ease
Kayentis (Paris, France) is out with a digital pen and paper technology product, called Clin'Form, designed to streamline handwritten entry of clinical trial data into an electronic CRF through a collaborative, Web-based portal. The product is based on the Forms Automation System architecture using the Anoto Digital Pen & Paper technology.
Clin'Form enables a complete audit trail with full information traceability for data captured with digital pens. Also, tracking key users, including trial investigators, CRAs, and data managers, is possible, as well as study progress reports in real time on such measures as center openings, patient inclusion rates, and CRF completion follow-up. Once collected, Clin'Form facilitates the push of data to clinical data management systems in CDISC-compatible format, adding to its versatility.
Kayentis, (609) 627-5300, www.kayentis.fr
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
